The only FDA-approved injectable treatment of vesicoureteral reflux (VUR), a malformation of the urinary bladder that affects 1% of children worldwide. VUR can cause severe infections of the urinary tract and lead to irreversible kidney damage.
IF YOUR CHILD HAS VUR,
DEFLUX IS HERE TO HELP.
A urinary tract infection, or UTI, can be painful for a child and frustrating for a parent. But febrile UTIs (a UTI accompanied by a fever) or multiple UTIs can be a sign that something else is going on – quite possibly, VUR.
Deflux is indicated for treatment of children with vesicoureteral reflux (VUR) grades II-IV.
THERE IS GOOD NEWS.
IF YOUR CHILD HAS VUR, YOU HAVE OPTIONS.
Having a child with VUR can be a frustrating experience. Your child is one of the 1%, so you may not know who you can talk to about VUR. Learning about vesicoureteral reflux (VUR), how it affects your child and VUR treatments can be intimidating. This site can help.
DISCUSSING VUR WITH FRUSTRATED
PATIENTS CAN BE A CHALLENGE.
If you have patients with vesicoureteral reflux (VUR), you may wonder about the best way to approach their parents.
Also, after reading about Deflux, you may have questions that a sales representative would be qualified to answer. We can assist with both.
The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient. The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries. Deflux is a registered trademark of Nestlé Skin Health S.A. used under license.
Deflux® (hyaluronic acid/dextranomer) is contraindicated in patients with any of the following conditions: non-functional kidney(s), hutch diverticulum, ureterocele, active voiding dysfunction, and ongoing urinary tract infection.
Safety and efficacy of treatment of duplex systems, use of more than 6 mL of Deflux (3 mL at each ureteral orifice) at the same treatment session, and treatment of children under 1 year of age have not been established.